期刊文献+

左西孟旦治疗老年难治性心力衰竭的血流动力学改变和临床疗效 被引量:8

原文传递
导出
摘要 目的:观察左西孟旦治疗老年难治性心力衰竭的临床表现、血流动力学、脑钠肽变化。方法应用左西孟旦治疗老年难治性心力衰竭患者25例,观察治疗前后临床表现的变化,并测定血流动力学和脑钠肽指标。结果25例患者中,显效13例,有效7例,无效5例,总有效率为80%(20/25)。应用左西孟旦治疗前后各指标变化情况:治疗前后心率、平均动脉压比较差异无统计学意义(P>0.05);治疗24 h后和治疗1周后心输出量(CO)、心脏指数(CI)均较治疗前明显提高[(4.59±0.64)和(4.55±0.54) L/min 比(3.31±0.62) L/min、(3.00±0.32)和(3.03±0.30) L/(min·/m2)比(2.14±0.23)L/(min/m2)],肺毛细血管楔压(PCWP)、中心静脉压(CVP)和脑钠肽均较治疗前明显下降[(15.32±2.12)和(16.22±2.32)mmHg(1 mmHg=0.133 kPa)比(20.40±3.15) mmHg、(6.87±1.58)和(6.69±1.68) mmHg 比(9.26±3.16) mmHg、(620.6±305.6)和(600.8±289.6)ng/L比(1201.4±750.6)ng/L],差异有统计学意义(P<0.05)。应用左西孟旦后,2例出现恶心、不适感,但不影响治疗;1例发生室性期前收缩,经纠正低钾血症后消失。结论左西孟旦治疗老年难治性心力衰竭安全有效。
出处 《中国医师进修杂志》 2016年第9期850-852,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献12

  • 1McMurray JJ, Adamopoulos S, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology, Developed in collaboration with the heart failure association (hfa) of the esc[J]. Eur J Heart Fail, 2012, 14(8): 803-869.
  • 2Yi GY, Li JX, Zhang J, et al. Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis[J]. Med Sci Monit, 2015, 21: 895-901.
  • 3鄢飞奔.米力农与多巴酚丁胺治疗重度充血性心力衰竭的疗效比较[J].吉林医学,2011,32(35):7489-7490. 被引量:1
  • 4杜贺,史承勇,陈少萍.左西孟旦的研究新进展[J].中国循环杂志,2014,29(7):555-557. 被引量:66
  • 5Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis[J]. Heart, 2011, 97(12): 959- 963.
  • 6邹继红,张秋英,刘影.慢性心衰合并房颤患者血浆脑钠肽的变化及意义[J].世界中西医结合杂志,2015,10(1):72-74. 被引量:6
  • 7郝国贞,高恒波,范卫泽,杨静静,汪雁博,姜云发,谷新顺,傅向华.左西孟旦治疗老年慢性心力衰竭的效果与安全性评价[J].中国全科医学,2015,18(26):3153-3157. 被引量:54
  • 8Nieminen MS, Ahenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus[J]. Int J Cardiol, 2014, 174(2): 360-367.
  • 9Papp Z, l~des I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on themechanisms of action of levosimendan[J]. Int J Cardiol, 2012, 159 (2): 82-87.
  • 10Silvetti S, Greco T, Di Prima AL, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta- analysis of randomised trials[J]. Clin Res Cardiol, 2014, 103(7): 505-513. DOE 10.1007/s00392-013-0649-z.

二级参考文献88

  • 1张耀春,王彦,王立为.左西孟旦的药理、毒理学研究综述[J].中国药物应用与监测,2005,2(1):59-61. 被引量:20
  • 2甄锦焕,张顺遂.依贝沙坦对扩张型心肌病的心室重塑和心功能的影响[J].岭南心血管病杂志,2005,11(1):22-23. 被引量:6
  • 3付海霞,张嘉莹,李庚山,许家俐.慢性心力衰竭患者血浆脑钠肽水平研究[J].实用诊断与治疗杂志,2006,20(10):705-707. 被引量:25
  • 4杨跃进.心力衰竭的进展(12)心力衰竭药物治疗的研究进展(续7)[J].中国循环杂志,2006,21(6):407-411. 被引量:12
  • 5Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology[J].. Eur Heart J, 2005, 26(4) :384- 416.
  • 6Yancy CW, Sahzberg MT, Berkowitz RL, etal. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting ( from the FUSION I trial) [J]. AmJ Cardioh 2004, 94(5) 595-601.
  • 7Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency ( from the Follow Up Serial Infusions of Nesiritide [ FUSION I] trial) [J]. Am J Cardiol,2006, 98 (2) 226-229.
  • 8Yancy CW, Krum H, Massie BM, et al. The Second Follow up Serial Infusions of Nesiritide ( FUSION II ) trial for advanced heart failure: study rationale and design[J]. Am Heart J, 2007, 153(4) 478- 484.
  • 9Hernandez AF, O'Connor CM, Starling RC,et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCENI> HF) [J]. Am Heart J, 2009, 157(2): 271- 277.
  • 10Kivikko M, Lehtonen L. Levosimendan: A new inodilatory drug for the teatment of decompensated heart failure [J].Curr Pharm Des, 2005, 11(4) : 435-455.

共引文献141

同被引文献78

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部